[go: up one dir, main page]

PE20081461A1 - Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua - Google Patents

Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua

Info

Publication number
PE20081461A1
PE20081461A1 PE2007001385A PE2007001385A PE20081461A1 PE 20081461 A1 PE20081461 A1 PE 20081461A1 PE 2007001385 A PE2007001385 A PE 2007001385A PE 2007001385 A PE2007001385 A PE 2007001385A PE 20081461 A1 PE20081461 A1 PE 20081461A1
Authority
PE
Peru
Prior art keywords
water
pharmaceutical dosage
dosage forms
insoluble ionic
solid pharmaceutical
Prior art date
Application number
PE2007001385A
Other languages
English (en)
Inventor
Antonio A Albano
Wantanee Phuapradit
Navnit Hargovindas Shah
Zhongshui Yu
Lin Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081461A1 publication Critical patent/PE20081461A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA FORMA SOLIDA DE DOSIFICACION FARMACEUTICA DE ADMINISTRACION ORAL QUE COMPRENDE UN COMPUESTO ACTIVADOR DE GLUCOQUINASA TAL COMO 2(R)-(3-CLORO-4-METANOSULFONIL-FENIL)-3-[1(R)-3-OXO-CICLOPENTIL]-N-(PIRAZIN-2-IL)-PROPIONAMIDA O 2(R)-(3-CLORO-4-METANOSULFONIL-FENIL)-3-CICLOPENTIL-N-[5-(1(S),2-DIHIDROXIETIL)-PIRAZIN-2-IL]-PROPIONAMIDA, EN UNA FORMA CRISTALINA O AMORFA FISICAMENTE INESTABLE, MICROINCLUIDO EN UN POLIMERO IONICO INSOLUBLE EN AGUA SELECCIONADO DEL GRUPO QUE INCLUYE COPOLIMEROS DE ACIDO METACRILICO, ETILETACRILATO, METILETACRILATO, ENTRE OTROS, DONDE LA PROPORCION DEL COMPUESTO Y EL POLIMERO ES DE 5:1 A 1:5 RESPECTIVAMENTE, Y ADEMAS SE DEPOSITA SOBRE UNA ESFERA DE CELULOSA MICROCRISTALINA, OBTENIENDOSE UNA FORMA DE DOSIFICACION CON UN PERFIL DE DISOLUCION RAPIDO, REPRODUCIBLE Y COMPLETO; SIENDO UTIL EN EL TRATAMIENTO DE DIABETES TIPO 2
PE2007001385A 2006-10-13 2007-10-12 Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua PE20081461A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85185206P 2006-10-13 2006-10-13
US95440107P 2007-08-07 2007-08-07

Publications (1)

Publication Number Publication Date
PE20081461A1 true PE20081461A1 (es) 2008-10-18

Family

ID=38857877

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001385A PE20081461A1 (es) 2006-10-13 2007-10-12 Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua

Country Status (16)

Country Link
US (1) US20080107725A1 (es)
EP (1) EP2079447A1 (es)
JP (1) JP2010505901A (es)
KR (1) KR20090053858A (es)
AR (1) AR063259A1 (es)
AU (1) AU2007306402A1 (es)
BR (1) BRPI0719880A2 (es)
CA (1) CA2665604A1 (es)
CL (1) CL2007002921A1 (es)
IL (1) IL197871A0 (es)
MX (1) MX2009003516A (es)
NO (1) NO20091274L (es)
PE (1) PE20081461A1 (es)
RU (1) RU2009117711A (es)
TW (1) TW200824709A (es)
WO (1) WO2008043701A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2744498A4 (en) * 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
EP3228307A1 (en) * 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
JP6913180B2 (ja) * 2016-12-15 2021-08-04 華領医薬技術（上海）有限公司Ｈｕａ Ｍｅｄｉｃｉｎｅ （Ｓｈａｎｇｈａｉ） Ｌｔｄ． グルコキナーゼ活性化剤の経口製剤およびその製造方法
AU2019278015B2 (en) * 2018-05-31 2024-10-03 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
CA2277220A1 (en) * 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
BR0110492A (pt) * 2000-05-03 2003-04-08 Hoffmann La Roche Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto
JP5178982B2 (ja) * 2000-05-18 2013-04-10 セリックス， インコーポレイテッド 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化
EP2305648A1 (en) * 2001-12-21 2011-04-06 Novo Nordisk A/S Amide derivatives useful as glucokinase activators
EP1496052B1 (en) * 2002-03-26 2009-08-05 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
WO2003090717A1 (en) * 2002-04-23 2003-11-06 Nanotherapeutics, Inc Process of forming and modifying particles and compositions produced thereby
PE20040801A1 (es) * 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
JP2007507489A (ja) * 2003-09-30 2007-03-29 ソルベスト リミテッド 水可溶性ナノ粒子封入複合体

Also Published As

Publication number Publication date
JP2010505901A (ja) 2010-02-25
MX2009003516A (es) 2009-04-14
WO2008043701A1 (en) 2008-04-17
RU2009117711A (ru) 2010-11-20
AU2007306402A1 (en) 2008-04-17
CL2007002921A1 (es) 2008-05-30
EP2079447A1 (en) 2009-07-22
BRPI0719880A2 (pt) 2014-06-10
US20080107725A1 (en) 2008-05-08
KR20090053858A (ko) 2009-05-27
CA2665604A1 (en) 2008-04-17
IL197871A0 (en) 2009-12-24
TW200824709A (en) 2008-06-16
NO20091274L (no) 2009-05-28
AR063259A1 (es) 2009-01-14

Similar Documents

Publication Publication Date Title
PE20081461A1 (es) Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua
EP2351757A4 (en) RAPAMYCIN-CARBON ACID ANALOGUE, PHARMACEUTICAL COMPOSITIONS, PREPARATIONS AND THEIR USE
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
UY29835A1 (es) Formas de dosificación farmacéutica sólidas que comprenden 5-cloro-n-(((5s)-2-oxo-3-(4-(3-oxo-4-morfolinil)fenil)-1,3-oxazolidin-5-il)metil)-2-tiofenocarboxamida
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
UY28493A1 (es) Metanosulfonato del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propiónico y su utilización como medicamento.
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
CL2008000219A1 (es) Composicion farmaceutica de liberacion modificada que comprende a uno o mas ingredientes farmaceuticamente activos, con solubilidad dependiente del ph, un polimero controlador de la liberacion, agentes facilitadores de la gelificacion; procedimiento
CU23551B7 (es) Procedimiento para la producción de una composición farmacéutica sólida de administración oral
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
GEP20125487B (en) Organic compounds and their use
AR084610A1 (es) Comprimido de desintegracion oral de lansoprazol
EA200970726A1 (ru) Твердый препарат, содержащий алоглиптин и пиоглитазон
BR112013031510A2 (pt) [1,3]oxazinas
UY29575A1 (es) Formas polimórficas del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino--imino-metil)-fenilamino)-metil)-1-metil-h-bencimidazol-5-carbonil)-piridin-2-il- -amino)-propiónico
EP2214231A4 (en) POSITIVE ELECTRODE ACTIVE MATERIAL, MANUFACTURING METHOD AND ELECTROCHEMICAL EQUIPMENT
AR086249A1 (es) Composiciones de tabletas de disolucion rapida de administracion vaginal
EP2444532A4 (en) IODINE- AND AMYLASE-CONTAINING FIBERS, PROCESS FOR THEIR PREPARATION AND USE
DE112007001669A5 (de) Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung
PE20091392A1 (es) Composiciones farmaceuticas como agentes antiinflamatorios
SMT201400014B (it) Stabilita' di dissoluzione migliorata di compressedi carbonato di calcio
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
PE20130403A1 (es) Comprimido de desintegracion via oral que contiene acarbosa

Legal Events

Date Code Title Description
FC Refusal